STOCK TITAN

Accelerate Diagnostics Scheduled Call to Review 2023 Fourth Quarter and Full Year Results.

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Accelerate Diagnostics, Inc. (AXDX) will host a conference call to review 2023 fourth quarter and full year results on March 28, 2024, at 4:30 p.m. Eastern Time. The call can be accessed online or by phone with replay options available.
Positive
  • None.
Negative
  • None.

TUCSON, Ariz., March 7, 2024 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced today that management will host a conference call on Thursday, March 28, 2024, at 4:30 p.m. Eastern Time to review 2023 fourth quarter and full year results.

To listen to the audio webcast online, visit ir.axdx.com. A replay of the audio webcast will be available for 30 days.

To listen by phone, dial +1.877.883.0383 and enter the Elite Entry Number: 7172610. International participants may dial +1.412.902.6506. Please dial in 10-15 minutes prior to the start of the conference.

A replay of the call will be available by telephone at +1.877.344.7529 (U.S.) or +1.412.317.0088 (International) using the replay code 7585609 until April 18, 2024.

About Accelerate Diagnostics, Inc.

Accelerate Diagnostics, Inc. is an in vitro diagnostics company dedicated to providing solutions for the global challenges of antibiotic resistance and sepsis. The Accelerate Pheno® system and Accelerate PhenoTest® BC kit combine several technologies aimed at reducing the time clinicians must wait to determine the most optimal antibiotic therapy for deadly infections. The FDA cleared system and kit fully automate the sample preparation steps to report phenotypic antibiotic susceptibility results in approximately 7 hours direct from positive blood cultures. Recent external studies indicate the solution offers results 1-2 days faster than existing methods, enabling clinicians to optimize antibiotic selection and dosage specific to the individual patient days earlier.

The "ACCELERATE DIAGNOSTICS" and "ACCELERATE PHENO" and "ACCELERATE PHENO TEST" and "ACCELERATE WAVE" and diamond shaped logos and marks are registered trademarks of Accelerate Diagnostics, Inc.

For more information about the company, its products and technology, or recent publications, visit axdx.com.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/accelerate-diagnostics-scheduled-call-to-review-2023-fourth-quarter-and-full-year-results-302081894.html

SOURCE Accelerate Diagnostics, Inc.

FAQ

When will Accelerate Diagnostics, Inc. host the conference call to review 2023 fourth quarter and full year results?

Accelerate Diagnostics, Inc. will host the conference call on March 28, 2024, at 4:30 p.m. Eastern Time.

How can I access the conference call online?

To access the conference call online, visit ir.axdx.com.

What is the phone number to dial for listening to the conference call?

To listen by phone, dial +1.877.883.0383 and enter the Elite Entry Number: 7172610.

How long will the replay of the audio webcast be available?

The replay of the audio webcast will be available for 30 days.

What is the replay code for accessing the call by telephone?

The replay code for accessing the call by telephone is 7585609.

Accelerate Diagnostics, Inc.

NASDAQ:AXDX

AXDX Rankings

AXDX Latest News

AXDX Stock Data

20.26M
13.50M
36.96%
12.06%
1.35%
Analytical Laboratory Instrument Manufacturing
Manufacturing
Link
United States of America
TUCSON

About AXDX

accelerate diagnostics, inc. (nasdaq:axdx), is an in vitro diagnostics company focused on developing and commercializing innovative systems for the rapid identification and antimicrobial susceptibility testing of infectious pathogens. the company's revolutionary id/ast platform utilizes a proprietary process with both genomic and phenotypic detection technologies that significantly decreases time to result while achieving high sensitivity and specificity. in addition to the id/ast development pipeline, the company also owns and licenses its proprietary optichem™ surface coatings technology, which has numerous applications for binding in bio-analytical systems, such as microarrays.